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L. Norgren*
Department of Surgery, University Hospital Orebro, S 70185 O¨rebro, SwedenThe systematic review presented in this article was
prompted by the fact that the European Guidelines
for drug trials in critical limb ischemia (CLI) only ac-
cept complete ulcer healing as the primary endpoint.1
The use of this endpoint after revascularization was
questioned. The authors concluded, after thorough
review of the literature, that complete ulcer healing
was reported infrequently and studies reporting this
outcome had a low level of evidence; no randomized
controlled trials were found.
Therefore the question is raised as to whether com-
plete ulcer healing is the most relevant single primary
endpoint for drug trials in CLI.
Patients with the most advanced stages of periph-
eral arterial occlusive disease (PAOD), commonly
classified as Fontaine stage III and Fontaine stage IV
including those with rest pain and ulcers/gangrene
respectively, have a poor prognosis, with an annual
mortality rate of about 20% and limited treatment op-
tions. First choice treatment is endovascular or open
surgical repair, should technical prerequisites be
met. The main pathophysiological findings are multi-
level blocked large arteries combined with severe
microcirculatory malfunction and therefore dramatic
response to medical or other treatments can not be
expected.
The Trans-Atlantic conference on clinical trial
guidelines in PAOD2 recommended the following
primary endpoints for the treatment of CLI: complete
relief of pain without analgesia for Fontaine stage III
and complete ulcer healing of both legs for Fontaine
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mary endpoint. Partial healing of ulcers is of limited
clinical significance and therefore not an acceptable
endpoint. The most important primary endpoint is
composite, including all-cause mortality, cardiovascular
morbidity and amputation, and this was recommen-
ded to be superior to single endpoints.
Response-based endpoints were also discussed, the
optimal response would be a living patient, with two
legs, having no ulcers and free from pain without
analgesia. With improved and refined quality of life
instruments, QoL assessment also might be a relevant
endpoint.
Regulatory Authorities’ Aspects
Interestingly, the FDA does not provide published
guidelines on endpoints, but usually approves
amputation-free survival as the primary endpoint.
Normally ulcer healing and pain relief are not
approved primary endpoints.
On the other hand there is always a negotiation
between the study sponsor and the FDA to decide
the most valid endpoint(s) for a specific trial.
The European Guidelines1 accept for Fontaine
stage III trials, the concept of ‘‘complete relief of
pain while off analgesics’’ and connects this with
absence of development of ischaemic lesions.
For Fontaine stage IV trials, the European Guide-
lines state that ‘‘generally, patients eligible for surgical/
interventional reconstruction should not be included’’,
a fact that reduces the chance of treatment effect,
due to advanced disease. As primary endpoint in
stage IV, only ‘‘complete healing of all necroses and
ulcerations’’ is accepted, while pain, consumption oferved.
318 L. Norgrenanalgesics, hemodynamics, interventions and QoL are
all secondary endpoints.
The response based endpoint, patient being alive,
having both legs, no wound or pain and off analgesics
also is listed.
The European Guidelines also present recommen-
dations for prevention (of ischaemic events) trials,
claiming a composite endpoint to be most relevant.
Revascularization Endpoints
As clearly shown by the authors, complete ulcer heal-
ing is rarely used as an endpoint after revasculariza-
tion. It also is evident that studies to evaluate the role
of a revascularization procedure are usually not
designed as randomized trials with a comparator
‘‘standard’’ procedure. Observational studies are more
common and although not providing level 1 evidence
may be relevant for practical consideration of the role
of the revascularization procedure under study, partic-
ularly if standard reporting criteria are used for inclu-
sion and for outcome evaluation. An example endpoint
is ‘‘limb salvage’’ or better a composite endpoint of
event-free survival. Events should include major
amputation, non-healing of ulcers, residual ischaemic
pain, myocardial infarction and ischemic stroke.3
Can Drug Trials and Revascularization
Studies be Compared?
First, trials comparing drugs with revascularizations
have not been performed so far! The second question
is whether drug trials can be compared to revascular-
ization trials. This is obviously difficult for several
reasons, one being that included patients differ
considerably: those selected for drug trials should nor-
mally be non-reconstructable (for technical reasons or
due to contraindications). The multilevel vascular
lesions in the leg of these patients are usually part of
a generalized disease with poor prognosis. Those
with reconstructable vascular lesions may have
a slightly better outcome and revascularization always
should be considered the first option.4 Another differ-
ence is that revascularization only affects leg symp-
toms, while drug treatment has systemic effects. For
these reasons no single endpoint is relevant for all
types of treatment trials in CLI. On the other hand,
composite endpoints, describing the outcome of theEur J Vasc Endovasc Surg Vol 33, March 2007patient and the leg may be reasonable to use for any
treatment option used in well conducted trials.
To summarize, the authors suggest that complete
ulcer healing should not be used as the single primary
endpoint in drug trials for CLI and claim that having
a different primary endpoint from those recommen-
ded for revascularization studies is unjustified. They
propose endpoints that are ‘‘both clinically relevant
and realistic and should apply to pharmacotherapy
and revascularization procedures’’ equally, indicating
that amputation-free survival, the functional status of
the patient and quality of life are more appropriate
alternatives. To use a composite endpoint also seems
to be a good alternative, but as discussed above, this
has to include complete ulcer healing. I fully agree
that response-based endpoints are valuable as they
will consider time to response, provided ‘‘response’’
is uniformly defined.
Quality of life assessment must be considered. Such
parameters are very important to the patient, but
require good working instruments for the symptoms
and disease in question.
If, in the future, medical treatment could be directly
compared with revascularization, including patients
with more uniform entry criteria, the role of compos-
ite endpoints might become even more important.
Requirements for such trials have to be potentially
more effective medical therapies and an acceptance
of delayed revascularization, where this is a potential
treatment option.
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